Self Study Module 2: Novel Therapies
Launch Date:
September 23, 2021
September 23, 2021
This module will cover novel therapies for beta-thalassemia that are in late stage clinical development or have been recently approved.
Sujit Sheth, MD
Chief, Division of Pediatric Hematology/Oncology
Vice Chair of Clinical Research, Department of Pediatrics
Professor of Clinical Pediatrics, Department of Pediatrics
Weill Cornell Medical Center
Attending Pediatrician
New York-Presbyterian Komansky Children's Hospital
New York, NY
Dr. Sujit Sheth is the Chief of the Division of Pediatric Hematology/Oncology and Professor of Clinical Pediatrics at Weill Cornell Medicine and an Attending Pediatrician at NewYork-Presbyterian Phyllis and David Komansky Children's Hospital and Weill Cornell Medical Center. He is also Vice Chair of Clinical Research in the Department of Pediatrics at Weill Cornell Medicine. Dr. Sheth is board-certified in pediatrics and pediatric hematology/oncology, and is an expert in iron metabolism, thalassemia, and sickle cell disease.Dorothy Kleinert, DNP, MPH, MA, ANP, CPNP
Pediatrics – Thalassemia Clinical Research
Weill Cornell Medicine
New York, NY
Dorothy Kleinert received her Doctor of Nursing Practice (DNP) degree at Case Western Reserve University and her Pediatric Nurse Practitioner (PNP) degree at New York University, where she also received her MA degree in Adult Primary Care. She has also completed her Master of Public Health degree (MPH) at Columbia University.1.
Incorporate efficacy and safety data in novel approaches in treating β-thalassemia including erythroid maturation agents and gene therapies.
